When is comes to headhunting stocks, the biotech sector is an absolute breeding ground for growth opportunities.

Massive growth opportunities, but the caveat here isn’t so simple…

The real question is who actually has a technology that will make it to market in our immensely complicated healthcare system, and show profits for their endeavor?

There are more than a few variables that influence the successful launch of a new medical therapy/device.

Difficulty investing in the medical sector comes from one’s ability (or lack thereof) to discern quality science from quasi-experimental data.

Many times, press releases are written by the scientists themselves (or another equally experienced healthcare professional) and many of the details expressed by the company requires a Ph.D to decipher.

One sentence from $GTBP’s most recent press release is a perfect example.

One sentence…

In preclinical testing led by Dr. Jeffrey Miller, M.D., Deputy Director Masonic Cancer Center and Dr. Timothy Schacker, M.D., Medical School and Director, Program in HIV Medicine, the research team designed a series of Bispecific and Trispecific Natural Killer Cell Engagers (BiKE and TriKE) constructs to direct Natural Killer cell mediated cytotoxicity against an HIV infected target.

That my friends is a mouthful…

With so many references and nods, it’s hard to track what information is actually being disseminated.

Which brings me specifically to GT Biopharma, $GTBP.

Let me set the stage:

At the end of 2018 GT Biopharma presented positive data of their Tri-specific NK Cell Engager (TriKE) at the 60th American Society of Hematology (ASH) Annual Meeting.

Click here for the full article from December, 2018.

Positive results are good… but what’s better is when a company discovers something so potentially impactful that they completely restructure their management team to put the proper relationships in place.

What do I mean by proper relationships?

Mr. Cataldo already has a billion dollar company under his belt, and has proven himself to be a capable leader.

Anthony J Cataldo has been named Chairman and Chief Executive Officer. Mr. Cataldo founded and served as Chairman and Chief Executive Officer at Iovance Biotherapeutics, Inc. He created Iovance with assets purchased from the National Cancer Institute (NCI). Dr. Steven Rosenberg developed the autologous cell therapy technologies of the National Cancer Institute for the treatment of stage four melanoma. Iovance has a market capitalization over $1.3 billion.

Also take into account that this technology is on the cutting edge of science, and is a product of a very established university – The Masonic Cancer Center at the University of Minnesota.

Mr. Cataldo founded GT Biopharma on the NK cell technology developed by Dr. Jeffrey Miller, Director of the Masonic Cancer Center at the University of Minnesota. The NK cell technology was created for the treatment of solid and liquid tumors. Currently, two FDA clinical trials (phase one and phase two) are underway for the NK cell technology.

Now, what makes this technology so appealing is the scope of application.

Targeting both liquid and solid tumors significantly expands the marketing potential of such therapies.

Take into account a few recent acquisitions…

Most recently KITE Pharma was bought by Gilead Sciences, Inc. for $12 Billion (NASDAQ: GILD) and Juno Therpeautics was accuried ($9 Billion) by Celegene Corporation (NASDAQ: CELG). These highly expensive cell therapies are limited to only liquid tumors (20% of the cancer market).

These companies sold big, real big, and only serviced 20% of the cancer market.

Now let’s look at $GTBP’s most recent developments.

$GTBP just released positive results of their second phase trial in conjunction with the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 31 – June 4.

With the annual meeting concluding just one week ago, this information is still being digested by the medical community, and the company is continuing to move forward.

Mr. Anthony Cataldo, the Chairman and Chief Executive Officer of GT Biopharma commented: “GTB-1550 has shown positive results in its two Phase I-II clinical trials in advanced cancer patients who have failed all other therapies, and we are now planning to proceed with a Phase II clinical trial.”

That being said, we now have a forward looking date of when we expect more information to become available regarding this exciting breakthrough.

GTB-3550 (OXS-3550) is the Company’s first Tri-specific NK cell Engager (TriKE) product candidate being initially developed for the treatment AML. GTB-3550 (OXS-3550) is being readied to begin enrolling patients with advanced Acute Myeloid Leukemia (AML) in a Phase I/II expansion clinical trial starting mid- July 2019.

With a PhaseI/II clinical trial expansion beginning this July, expect more news and updates to come at lightening speeds.

If this therapy proves to be an effective cancer treatment for both solid and liquid tumors, and helps stifle the HIV epidemic… Look for $GTBP’s buyout options to dwarf those that only targeted 20% of the market.

Think about it… 🤔

You can read all of GT Biopharma’s Press Releases on their OTC Profile at: https://www.otcmarkets.com/stock/GTBP/news